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Clinicians across specialties are increasingly aware of health risks associated with 
vitamin D deficiency (VitD-). The link to bone health is obvious, but there is 
mounting evidence of associations with disorders including autoimmune and 
cardiovascular, diabetes, and various cancers (1). Vitamin D is endogenously 
synthesised in the skin by ultraviolet radiation or orally ingested (2). In the UK, few 
foods are supplemented with vitamin D, therefore, the main source is sun exposure. 
Unfortunately, patients in much of the UK are exposed to a UV index <3 for almost 
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half the year, significantly limiting their ability to obtain vitamin D from this 
modality.  
Patients diagnosed with melanoma are advised to avoid sun exposure to reduce 
further melanoma risk; thus at danger of rendering them VitD- with long-term health 
consequences. Data from the Leeds melanoma cohort suggested that sub-optimal 
vitamin D may be associated with poorer survival (2). Vitamin D has anti-
proliferative effects on melanoma cell lines in-vitro, which have been linked to the 
vitamin D signalling pathway (3). Vitamin D metabolites can inhibit proliferation and 
induce differentiation in melanoma cells (4). Furthermore, vitamin D receptors are 
found on all immune cells (5), though precise association with immune-competence 
and cancer progression/regression is unclear.  
We established a vitamin D (25-hydroxyvitamin D2/3) testing service for melanoma 
patients according to previous protocols (2,6). Patients are tested at: 
- Primary diagnosis 
- Routine follow-up (two years after primary diagnosis, annually thereafter) 
- At recurrence  
We aimed to determine the effects of sun avoidance advice on vitamin D levels in 
these cohorts, thereby auditing the feasibility and utility of offering this service at our 
centre.  
 
A prospectively-planned audit was registered and undertaken one year after 
establishing our testing service. We identified all melanoma patients who underwent 
vitamin D testing from May 2013-April 2014. Normal serum vitamin D level ranged 
from 50-120nmol/L according to local guidelines. Accordingly, for the purpose of this 
audit, we classified levels <50 nmol/L as deficient (regardless of terminology use in 
other references) since this indicated the level at which we would recommend 
supplementation. Parameters examined included patient demographics, tumour 
characteristics and vitamin D levels. Statistical analysis was performed using two-
tailed Mann-Whitney U-test and Chi2 analysis for comparing between patients at 
diagnosis and routine follow-up. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
407 melanoma patients who underwent vitamin D testing were identified. 102 patients 
were tested at primary melanoma diagnosis; 289 at follow-up and 16 at recurrence. 
Median age was 66 years (21-90 years). Female to male distribution was equal 
(153:154). 
 
 Table 1 summarizes the results. Key findings were: 
- Overall incidence of vitamin D deficiency was 9% greater in the follow-up 
cohort compared to the primary diagnosis cohort (55% versus 46%, 
respectively; Mann-Whitney: p=0.017) 
- Vitamin D deficiency was significantly associated with ulcerated primary 
tumours (p=0.06) and those with a higher mitotic index (median 4/mm2 versus 
median 1/mm2, Mann-Whitney: p=0.012) 
- Age was linked to vitamin D deficiency in the primary and follow-up groups; 
patients aged ≥65 years were more likely to be  VitD- (p<0.000, P<0.001) 
- We found no seasonal variation in the vitamin D levels in all groups. 
 
Our audit has revealed a significant trend towards increasing vitamin D deficiency in 
melanoma patients in long-term follow-up, though initial incidence in melanoma 
patients at diagnosis was also high (46%). Older patients and those with higher-risk 
primaries were more likely to be VitD- and should be specifically targeted. Primary 
tumours in the VitD- cohort were associated with higher mitotic rate and ulceration; 
both characteristics have well-known-associations with lower survival probability (7). 
VitD- is common in the UK melanoma patient and is associated with risk of 
melanoma relapse (2). Currently, evidence is lacking regarding direct therapeutic 
value of vitamin D supplementation in melanoma patients and the need for further 
research in this area has been highlighted (8). 
At our centre, baseline vitamin D is measured at time of melanoma diagnosis. When 
levels are within normal range, dietary advice is given. If levels are <50nmol/L, 
vitamin D3 supplementation of 1200IU (30micrograms) is commenced once daily for 
at least 6 months. If severe deficiency is detected (<20nmol/L), then supplementation 
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is increased. Calcium levels are monitored six weeks after to ensure no unmasking of 
hyperparathyroidism. Vitamin D levels are re-checked at 6 months. If levels have 
moved into normal range, supplementation of 400IU (10micrograms) is advised 
during the winter months. There remains debate to ideal levels of vitamin D. Our 
local range is 50-120nmol/L, though higher level (60-85nmol/L), depending on the 
season, has been suggested as at this level, parathyroid hormone reach a basal level 
and is not reduced with vitamin D supplementation (6,9) 
 
Our data suggests that measuring vitamin D levels may be of benefit in melanoma 
patients, with appropriate supplementation prescribed according to local/NICE 
guidance (8,10). In future, as vitamin D testing becomes more widely available and 
the correction of deficiency more commonplace, this service is likely to be undertaken 
in primary care.  
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 Vitamin D levels <50 nmol/L ≥50 nmol/L 
Primary 
diagnosis 
(n = 102) 
Total 47 55 
Age ≤65 years 18 28 
>65 years 29 27 
Ulcerated primary tumour 17 11 
Unknown ulceration 2 4 
Median mitotic index (/mm2) 4 2 
Post-primary 
diagnosis 
(n = 289) 
Total 162 129 
 Age ≤65 years 83 61 
>65 years 79 66 
Ulcerated primary tumour 26 26 
Unknown ulceration 13 13 
Median mitotic index (/mm2) 3 3 
At recurrence 
(n = 16) 
Total 6 10 
 Age ≤65 years 3 2 
>65 years 3 8 
Ulcerated primary tumour 2 4 
Unknown ulceration 2 5 
Median mitotic index (/mm2) 8 8 
Table 1: Result summary.  
 
